BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 2002;24:440-446. [PMID: 12218590 DOI: 10.1097/00043426-200208000-00007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Fan TM. Murine and canine models of appendicular osteosarcoma. Curr Protoc Pharmacol 2007;Chapter 14:Unit 14.1. [PMID: 21948160 DOI: 10.1002/0471141755.ph1401s37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, Dyer MA. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett 2019;442:262-70. [PMID: 30395907 DOI: 10.1016/j.canlet.2018.10.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
3 Li YS, Liu Q, He HB, Luo W. The possible role of insulin-like growth factor-1 in osteosarcoma. Curr Probl Cancer 2019;43:228-35. [PMID: 30217668 DOI: 10.1016/j.currproblcancer.2018.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
4 Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA. A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov 2015;5:920-31. [PMID: 26084801 DOI: 10.1158/2159-8290.CD-15-0125] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
5 Bock O, Tessema M, Serinsöz E, von Wasielewski R, Büsche G, Kreipe H. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders. Leuk Res 2004;28:1145-51. [PMID: 15380337 DOI: 10.1016/j.leukres.2004.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Choi N, Kim S, Cho J, Kim BK, Cho YS, Jang JY, Baek CH. Exponentially growing osteosarcoma of mandible with acromegaly. Head Neck 2016;38:E2432-6. [PMID: 26879563 DOI: 10.1002/hed.24394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-85. [PMID: 16831079 DOI: 10.1586/14737140.6.7.1075] [Cited by in Crossref: 239] [Cited by in F6Publishing: 230] [Article Influence: 15.9] [Reference Citation Analysis]
8 van den Berg H. Biology and therapy of solid tumors in childhood. Update on Cancer Therapeutics 2006;1:367-83. [DOI: 10.1016/j.uct.2006.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Disruption of IGF‑1R signaling by a novel quinazoline derivative, HMJ‑30, inhibits invasiveness and reverses epithelial-mesenchymal transition in osteosarcoma U‑2 OS cells. Int J Oncol 2018;52:1465-78. [PMID: 29568964 DOI: 10.3892/ijo.2018.4325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
10 Tan ML, Choong PFM, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. Journal of Pharmacy and Pharmacology 2009;61:3-12. [DOI: 10.1211/jpp.61.01.0002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
11 Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep 2005;7:410-4. [DOI: 10.1007/s11912-005-0005-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009;28:247-63. [PMID: 19214708 DOI: 10.1007/s10555-009-9186-7] [Cited by in Crossref: 174] [Cited by in F6Publishing: 166] [Article Influence: 14.5] [Reference Citation Analysis]
13 Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008;3:228-31. [PMID: 18782081 DOI: 10.2174/157488708785700267] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.7] [Reference Citation Analysis]
14 Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. Oncotargets Ther. 2013;6:471-483. [PMID: 23667314 DOI: 10.2147/ott.s39987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
15 Ferrari S, Dondi M, Fanti S, Zoboli S, Giacomini S, Mercuri M, Bacci G. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm 2003;18:847-51. [PMID: 14629833 DOI: 10.1089/108497803770418391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
16 Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008;10:315-27. [PMID: 18754698 DOI: 10.2165/00148581-200810050-00005] [Cited by in Crossref: 179] [Cited by in F6Publishing: 160] [Article Influence: 13.8] [Reference Citation Analysis]
17 Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer 2014;61:749-52. [PMID: 24178953 DOI: 10.1002/pbc.24778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Review of Anticancer Therapy 2014;7:169-81. [DOI: 10.1586/14737140.7.2.169] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 9.9] [Reference Citation Analysis]
19 Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, Jubala CM, Getzy DM, Cutter GR, Modiano JF, Breen M. Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 2009;17:365-77. [PMID: 19337847 DOI: 10.1007/s10577-009-9028-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
20 Kim SY, Helman LJ. Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 2009;152:517-28. [PMID: 20213413 DOI: 10.1007/978-1-4419-0284-9_31] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
21 Ando K, Mori K, Verrecchia F, Marc B, Rédini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma 2012;2012:523432. [PMID: 22448123 DOI: 10.1155/2012/523432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
22 Ioannou M, Papagelopoulos PJ, Papanastassiou I, Iakovidou I, Kottakis S, Demertzis N. Detection of somatostatin receptors in human osteosarcoma. World J Surg Oncol 2008;6:99. [PMID: 18783595 DOI: 10.1186/1477-7819-6-99] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Mancarella C, Morrione A, Scotlandi K. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options. Cells 2021;10:2075. [PMID: 34440844 DOI: 10.3390/cells10082075] [Reference Citation Analysis]
24 Vyas R, Gupta N, Nimesh S. Chitosan nanoparticles for efficient and targeted delivery of anticancer drugs. Nanobiomaterials in Cancer Therapy. Elsevier; 2016. pp. 281-306. [DOI: 10.1016/b978-0-323-42863-7.00009-8] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C. Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer 2009;124:2042-9. [PMID: 19132750 DOI: 10.1002/ijc.24169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
26 PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011;28:493-503. [PMID: 21461590 DOI: 10.1007/s10585-011-9384-x] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 12.5] [Reference Citation Analysis]
27 Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist 2009;14:83-91. [PMID: 19126579 DOI: 10.1634/theoncologist.2008-0189] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
28 Yamamoto N, Tsuchiya H. Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going? Expert Opinion on Pharmacotherapy 2013;14:2183-93. [DOI: 10.1517/14656566.2013.827171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
29 Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol 2009;217:469-82. [PMID: 19148905 DOI: 10.1002/path.2499] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 8.3] [Reference Citation Analysis]
30 O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009;9:511-23. [PMID: 19374604 DOI: 10.1586/era.09.7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
31 Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013;109:2142-54. [PMID: 24064975 DOI: 10.1038/bjc.2013.578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
32 Kvols LK, Woltering EA. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006;17:601-8. [PMID: 16917205 DOI: 10.1097/01.cad.0000210335.95828.ed] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
33 Wang CH, Tang CW, Liu CL, Tang LP. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9(9): 1904-1908 [PMID: 12970873 DOI: 10.3748/wjg.v9.i9.1904] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
34 Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol 2004;21:285-95. [PMID: 15456957 DOI: 10.1385/MO:21:3:285] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treatment Reviews 2006;32:423-36. [DOI: 10.1016/j.ctrv.2006.05.005] [Cited by in Crossref: 383] [Cited by in F6Publishing: 356] [Article Influence: 25.5] [Reference Citation Analysis]